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Abstract
Background: Polypharmacy can yield various adverse outcomes for patients over the age
of 65. The lack of a standardized process and education for hospice nurses to implement
into their clinical practice can increase polypharmacy, which burdens patients and
families at the end of life.
Purpose: This quality improvement project aimed to increase hospice nurses' knowledge
and confidence to initiate deprescribing for non-essential or inappropriate medications
with hospice patients.
Methods: A multimodal educational program that incorporated evidenced-based
resources composed of STOPP Frail Criteria, Garfinkel algorithm, and the BUILD model
was presented at a community hospice agency. Pre- and post-intervention questionnaires
were used to assess the hospice nurses' level of knowledge and confidence with
deprescribing. Meetings with the hospice nurses and retrospective chart reviews were
also conducted to evaluate actual trends of deprescribing at the agency.
Results: The 25 hospice nurses who completed the program demonstrated increased
confidence and knowledge of deprescribing, polypharmacy, and the identification of
inappropriate medications using the STOPP Frail Criteria and Garfinkel algorithm. There
was an increase in patients who had inappropriate medications deprescribed.
Conclusion: Deprescribing and polypharmacy are significant issues that impact older
patients at end of life. Ongoing education and evaluation are recommended to improve
patients' overall symptom management and quality of life.
Keywords: polypharmacy, deprescribing, end of life, hospice, nurses, discontinuing
medications, pill burden
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Deprescribing Medications at the End of Life at a Community Hospice Setting

Introduction
As patients age and are diagnosed with life-limiting illnesses, palliative and
hospice care become an option to assist with their quality of life, symptom management,
and treatment burden. In end-of-life care, the focus of care and drug therapy shifts from
curative to comfort and palliation of symptoms (Duncan et al., 2020). Medications
prescribed to prevent or treat illnesses or preserve life become futile when patients
transition to end-of-life care. Hospice nurses must be educated on deprescribing
medications. The education should include patient age-related considerations, the
pharmacokinetics and pharmacodynamics of medications, and the value of discontinuing
non-essential drugs at the end of life. By applying a combination of knowledge,
algorithms, and evidence-based tools, hospice nurses will be able to deprescribe
unnecessary medications, thus enhancing symptom management, improving patient
outcomes, and lowering caregiver burden.
Background
Patients with advanced illness are prescribed multiple medications in the last year
of life, intensifying the risk of adverse consequences related to polypharmacy. Thompson
and colleagues (2019) defined polypharmacy as the "concomitant use of multiple
medications, typically five or more medications, whose harms outweigh the benefits and
use of medications are not indicated" (p. 172). A significant amount of medication
burden is placed on patients with advanced illnesses. According to McNeil and
colleagues (2016), "A substantial proportion of patients near the end of life were
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prescribed medications to control or prevent non-life-threatening comorbidities." Patients
may demonstrate increased drug toxicity, drug-to-drug interactions, and a lack of
effectiveness of these medications (Garner, 2019). Medicines prescribed to treat or
prevent illnesses at the end of life become ineffective due to the physical changes within
the body. The Centers for Medicare and Medicaid Services (CMS) expect maintenance
drugs used to treat or cure a condition should be discontinued as the focus of care shifts
from curative to palliative and comfort (Duncan et al., 2020, p. 1077). Statins,
anticoagulants, proton pump inhibitors, oral hyperglycemic agents, cholinesterase
inhibitors, and bisphosphonates are frequently ineffective and can be deprescribed among
patients nearing the end of life.
In 2017, more than 1.49 million Medicare beneficiaries enrolled in Hospice
services (National Hospice and Palliative Care Organization ([NHPCO]), 2019). Of the
beneficiaries enrolled in hospice, 30.6% were over 65 years of age, and 64.2% were over
80 years of age (NHPCO, 2019). Hospice patients are at considerable risk for
polypharmacy due to the continuation of medicines for underlying medical conditions
and the administration of new medications to assist with symptom burden (Duncan et al.,
2020, p. 1076).
Due to polypharmacy, hospice patients are at higher risk for adverse effects.
These negative effects include falls, confusion, medication interactions, and a longer
medication half-life (Thompson et al., 2019). Thus, deprescribing is an essential
intervention for improving patient outcomes, reducing polypharmacy, and reducing
caregiver burnout caused by medication regimens (Thompson et al., 2019).
Deprescribing is defined as reducing or discontinuing the use of medications that
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may cause harm or no longer be beneficial (Pype et al., 2018). Although the notion of
deprescribing is growing within healthcare, there is little evidence that a systematic
approach exists to assist hospice nurses in implementing it at the end of life.
Problem Statement
The risk of decreased quality of life among hospice patients is related to
providers' overprescribing inappropriate medications. The shortfall in education and
resources on deprescribing medications for hospice nurses is evidenced by inconsistent
nursing practice, resulting in increased patient symptom burden, such as increased falls,
nausea, pain, anxiety, and cognitive deficits. By integrating systematic evidence-based
tools and education, hospice nurses will incorporate their knowledge of deprescribing
into their clinical practice. The focus will decrease polypharmacy, lower pill burden, and
improve patient outcomes.
Analysis of Project Site
Deprescribing medications at the end of life is a global issue since there is no
standardized process for reducing polypharmacy among hospice patients. There is no
standardized process for deprescribing medications for hospice patients within this
community hospice agency. A lack of training for novice hospice nurses can lead to
inconsistent practice and low competence. Inappropriate drug identification is seldom
discussed with patients and families during clinical visits, resulting in polypharmacy, pill
burden, ineffective symptom control, and poor patient outcomes. Current nursing
education does not address the concepts of disease trajectory and deprescribing. Overall,
the knowledge deficit among hospice nurses on deprescribing has identified the need for
this quality improvement educational program. This program will address the deficits
presented previously, including the lack of education for hospice nurses around
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deprescribing medications and the absence of a standardized process for determining
which medications should be discontinued by hospice nurses.
Review of the Literature
Despite the increased use of inappropriate medications among hospice patients,
hospice nurses do not have enough educational preparation or the resources to integrate
deprescribing into clinical practice. The purpose of this critical appraisal of literature was
to identify and evaluate current deprescribing practices. According to the literature,
evidence-based approaches to deprescribing non-essential drugs for patients at the end of
life include the Good Palliative Care algorithm and the STOPP/Frail criteria.
The International Group designed the Garfinkel Good Palliative Geriatric Practice
(GPGP) algorithm for Reducing Inappropriate Medication Use and Polypharmacy,
founded in 2013. A group of physicians developed this tool to assist practitioners in
deprescribing inappropriate medications or decreasing the dose of medicines that may be
harmful (Bilek et al., 2019). The STOPP/Frail Criteria list of potentially inappropriate
prescribing indicators was designed to assist physicians with stopping such medications
in patients 65 years and older (Curtin et al., 2020). These evidence-based tools and
education assisted hospice nurses in identifying potentially inappropriate and futile
medications for hospice patients. These tools increased the clinician's knowledge base
and clinical practice strategies to integrate this knowledge to reduce symptoms and
improve patient safety and outcomes.
Search Strategy
A thorough review of the literature was conducted using four research databases,
including the Cumulative Index of Nursing and Allied Health Literature (CINAHL),
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Public Medline (PubMed), Science Direct, and Google Scholar. Inclusion criteria were
articles published between 2015-2020, articles that studied the deprescribing process and
tools, were peer-reviewed, written in the English language, and targeted patients at the
end of life. Exclusion criteria focused on pediatric patients under the age of eighteen,
articles not written in English, not peer-reviewed, and articles that did not pertain to end
of life. The MeSH terms and key terms included: polypharmacy, deprescribing, end of
life, hospice, nurses, discontinuing medications, STOPP/Frail Criteria, and pill burden.
Initial search results with CINAHL yielded 496 articles. Two hundred thirty-four
articles were omitted since they did not fall within the five-year period (2015-2020). Two
hundred thirty-two articles were excluded due to not meeting peer review and end of life
deprescribing criteria. Thirty articles focused on deprescribing at the end of life. Search
efforts through PubMed yielded 120 articles, but 118 were omitted due to the article's
publication date or duplication of articles. Science Direct and Google Scholar yielded 829
articles. Due to the title or duplication of the articles, 825 articles were discarded. Four
articles remained, which focused on deprescribing at the end of life. In total, 36 articles
remained after the review of all the articles.
The John Hopkins, Nursing Evidence Rating Tool, appraised the strength
and quality of evidence (Newhouse et al., 2005). The tool rates each article on the
strength of evidence I-V and the quality of evidence from A (high quality) to C (low
quality). The review of articles identified five articles Level I with an A rating for the
quality of evidence (Bilek et al., 2019; Curtin et al., 2020; Fournier et al.,2020; Kutner et
al.,2015; Martin & Tannenbaum, 2017). Ten articles were assigned Level IV for their
strength of evidence and rated B for quality of evidence (Burgle et al., 2020; Duncan et
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al., 2020; Farrell et al., 2015; Huisman et al., 2020; Morin et al. 2019; Paque et al., 2019;
Poudel et al., 2019; Pype et al., 2018; Schnecker et al., 2019; Thompson et al., 2019).
In addition, the Bruyere Institute in Canada established four clinical practice
guidelines, which were recognized (Farrell, Black, et al., 2017; Farrel, Ponte, et al., 2017;
Pottie et al., 2018; (Reeve et al., 2019). The guidelines rated level IV by the evidence
rating tool. Seven articles rated level V were reviewed as supportive data, which focused
on deprescribing (Collier et al., 2013; Endsley, 2018; Holmes & Todd, 2017; Stinson et
al., 2019; (Todd et al., 2018). Four level I articles were randomized control studies
(RCT), and one was a non-randomized control study. The level IV articles were
systematic reviews, cohort studies, literature reviews, and secondary analyses.
Findings
Inappropriate medication uses at end of life
Medicines prescribed for disease prevention become ineffective because the risk
of adverse outcomes outweighs the medication benefit during the end of life. As patients
near end-of-life, polypharmacy becomes a heightened factor that increases adverse
effects from medications such as confusion, potential increased risk for falls, and
symptom burden (Thompson et al.,2019). Three studies examined inappropriate
medications for patients at the end of life (Morin et al., 2017; Poudel et al., 2019; Pype et
al., 2018). Morin and colleagues conducted a randomized control trial with 58,415
participants in the last three months of life (2017). On average, patients had eight
medications prescribed; of those medications, 33% of participants had at least one drug
that was identified as futile or inappropriate, and 14% had one non-essential medicine
prescribed. Pype and colleagues conducted a retrospective chart review of 210 patients
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and identified 83% of participants within the last weeks of life were taking at least one
inappropriate medication (2018).
Researchers reviewed the time of the last prescription before study participants'
death, and polypharmacy occurred in 60% of the participants (Poudel et al., 2019). The
most common medications prescribed and continued were statins (38%) and vitamins
(30%). At the 6-month mark, 10% of patients were on statins. As the patients declined
into the last week of life, 6% of patients were still on statins and vitamins. In summary,
from these studies, it was apparent that hospice nurses and practitioners do not
consistently identify inappropriate medications for patients with a limited life expectancy.
Definition of deprescribing
The concept of deprescribing among patients nearing the end of life is complex.
Deprescribing is defined as reducing or discontinuing medications in a planned or
supervised manner (Thompson et al., 2018). Deprescribing helps minimize inappropriate
or potentially burdensome medications while optimizing the benefits of medication
therapy for patients. As patients near the end of life, the clinician's role is to identify
medicines that may be potentially futile or burdensome for the patient or family to
continue. There is limited research on the role of the hospice nurse in deprescribing.
Utilizing the systematic tools of the STOPP/Frail Criteria (See Appendix A) and
Garfinkel Good Palliative Geriatric Practice Algorithm (GPGP) (See Appendix B) will
assist hospice nurses in the identification of such medications.
Perceptions of deprescribing
Two articles focused on patients' and practitioners' perceptions of deprescribing.
(Burgle et al., 2020; Holmes & Todd, 2017). One common theme identified within the
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Burgle et al. (2020) study was that deprescribing medications involved the whole team of
practitioners, patients, and families. Patient-centered care is an essential factor when a
patient reaches end-of-life. At that time, the team should identify goals of care that are
important to the patient. When it comes to deprescribing medications for patients nearing
the end of their life, hospice nurses should consider the following factors: how the
medication regimen affects patients' daily lives, their time with family, the adverse
effects of the medication, and the convenience of the medication regimen.
Screening Tools for Deprescribing
The STOPP/Frail Criteria and GPGP Algorithm were used in six out of the thirty
articles. These tools assist practitioners and hospice nurses in identifying futile
medications for patients with terminal illnesses entering the final stages of the end of life.
The STOPP/Frail Criteria was developed in 2017 by a panel of 18 experts in
geriatric pharmacology in the United Kingdom (Lavan et al., 2017). The purpose of these
criteria is to guide practitioners in identifying potentially inappropriate medications.
The STOPP criteria has been utilized in many clinical trials, which has increased
the validity and reliability of the tool. Fournier et al. (2020) used the STOPP criteria if the
participants met specific criteria: end-stage irreversible pathology, poor one-year survival
prognosis, and severe functional impairment. Three hundred six participants met all three
criteria. Medications prescribed to these participants revealed that 13% were potentially
inappropriate by the STOPP criteria.
Curtin et al. (2017) conducted a clinical trial in Ireland which utilized the STOPP
criteria intervention for 51 participants within a sample size of 130. As a result of the
intervention of the STOPP criteria, 91% of the participants received recommendations to
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stop at least one inappropriate medication.
The Good Palliative Geriatric Practice (GPGP), also known as the Garfinkel
algorithm, was developed by a panel of experts in 2019 to assist practitioners in
deprescribing inappropriate medications at the end of life (Bilek et al., 2019). Bilek et al.
(2019) conducted a study among practitioners who received education and those did not.
The sample size was 100 patients. Overall, the study demonstrated that the practitioners
who received training prescribed 18.5% fewer medications than the control group.
Summary
There is extensive research regarding the potential adverse effects of
polypharmacy among patients at the end of life. The literature concludes that
inappropriate medications become futile at the end of life (Burgle et al., 2020), and
discontinuing inappropriate medications decrease polypharmacy for terminally ill patients
(Collier et al., 2013; Fournier et al., 2020; Poudel et al., 2019). However, no studies
identified the correlation between deprescribing and patient outcomes. In addition, there
is no systematic process for deprescribing that hospice nurses can utilize during their
daily practice. Hospice nurses needed more training to recognize ineffective drugs and
enforce deprescribing medications using evidence-based resources. Systematic processes
and evidence-based education can ensure hospice nurses take a consistent approach to
deprescribe medications for hospice patients at the end of life.
Theoretical Framework
This project followed the BUILD Model (Collier et al., 2013) (See Appendix C).
This model provided a framework for hospice nurses to develop relationships with their
patients and families, gain information about their current understanding of their
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medications, and facilitate discussions with patients and families about medication
appropriateness. The five components of this model consisted of:
•

Build: the hospice nurse should build a foundation of trust and respect by
listening to and validating the patients’/families' concerns.

•

Understand: the hospice nurse should assess the patient' understanding of
the medications they are currently taking and their knowledge of
deprescribing.

•

Inform: the hospice nurse should provide evidence-based knowledge to
the patient and family on the risks vs. benefits of continuing to take their
current medications.

•

Listen: the hospice nurse should provide time for the patient and family to
express their wishes, concerns, and goals related to medication.

•

Develop: the hospice nurse and patient/family should develop a patientcentered plan of care that incorporates discontinuing inappropriate
medications which is aligned with the patients' goals.
Project Design

Project Site and Population
The project was implemented at a community hospice agency in a rural
community with one local healthcare system. The population of the rural community in
2019 was 124,944. (U.S. Census, 2019). The hospice agency provided hospice services
within the healthcare system, including long-term care facilities, assisted living
communities, and independent homes. The hospice agency's rolling census averages
approximately 110 patients daily.
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The agency's largest referral source is the local healthcare system. The community
primary care providers serve as the patients attending physicians when they elect the
hospice service. Payment sources included Medicare, Medicaid, and commercial
insurances. The hospice nurses' patients had a life-limiting diagnosis of cancer, end-stage
cardiac disease, dementia, end-stage lung disease, or neurological disease such as
Parkinson's Disease.
The educational project was offered to 30 hospice nurses with enrollment
strategies, including flyers, staff meetings, word of mouth, and emails. There were 25
hospice nurses that voluntarily participated in the project.
The agency's nurse practitioner provided supervision for this quality improvement
project. Additionally, the agency's Executive Director and Director of Quality
Improvement supported the project's implementation (Appendix I).
Design
This quality improvement project provided hospice nurses with educational
sessions to build a shared understanding of deprescribing. The deprescribing tool kit
reviewed includes two screening tools, the STOPP Frail Criteria (Appendix A) and the
GPGP algorithm (Appendix B). The DNP student administered two pretests (a) a
knowledge questionnaire (Appendix F) and (b) a confidence ruler (Appendix G) before
conducting the educational intervention. After each educational session, the hospice
nurses completed a program evaluation (Appendix L).
The DNP student reviewed a skill-building case study during the last educational
intervention. (Appendix E) Then three post-intervention questionnaires were
administered to the participants (a) knowledge questionnaire, (b) confidence ruler, and (c)
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program evaluation questionnaire. The DNP student observed the current deprescribing
practices within this agency for 16 hours per week. In addition, the DNP student and the
mentor met with the hospice nurses monthly to ensure accurate utilization and the
identification of inappropriate medications that were being deprescribed.
Ethical Considerations/Protection of Human Subjects
The University of Massachusetts, Amherst (UMass) Institutional Review Boards
(IRB) approval was obtained before initiating the DNP Project (See Appendix H). Since
this is a quality improvement project, IRB approval for the clinical site was exempted
(see Appendix I). The pre-and post-surveys were assigned a number and letter code, so
staff remained anonymous. Patient records were assigned a patient ID to ensure that the
identity of individual patients was protected. All data, including assessments, surveys,
and deprescribing information, were stored in a locked cabinet in the Clinical Director's
office at the participating agency. There was no ethical risk posed to the patients since the
standard of care was provided regardless of their nurses' participation in the project.
Timeline and Budget
The project timeline details are in Appendix L. Detailed budget costs are in
Appendix K.
Methods
Implementation
Four educational sessions were conducted; each session was 60 minutes in length
and used a multimodal educational approach, including presentations, case studies, and
role-playing to enhance learning for each nurse (Appendix E). The number of hospice
nurses assigned to each session was between 7-10 people to conform to COVID safety
protocols and minimize the risk of exposure to hospice nurses during interactions.
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In educational session one, conducted in the first week of September 2021, the
DNP student reviewed the concept of deprescribing and prescribing cascade. In
educational session two, conducted in the second week of September 2021, the DNP
student reviewed the GPGP algorithm, STOPP Frail criteria, and National Hospice and
Palliative Care Deprescribing toolkit (NHPCO_Deprescribing_Toolkit., 2020). The
NHPCO tool kit integrates both the GPGP algorithm and STOPP criteria into patient
scenarios to demonstrate how to proceed with deprescribing techniques to achieve
patient-centered care. The DNP student provided each hospice nurse with a portable copy
of the tools to use in the clinical setting to educate patients and families about
inappropriate medications and deprescribing.
In educational session three, conducted in the third week of September 2021, the
DNP student introduced the BUILD model, which provided the framework for
facilitating discussions about deprescribing. During this session, the hospice nurses
learned how to integrate each of the five components into their communication process
with patients and families. The five components of this model consisted of:
•

Build: the hospice nurse should build a foundation of trust and respect by
listening to and validating the patients’/families' concerns.

•

Understand: the hospice nurse should assess the patient's understanding of
the medications they are currently taking and their knowledge of
deprescribing.

•

Inform: the hospice nurse should provide evidence-based knowledge to
the patient and family on the risks vs. benefits of continuing to take their
current medications.
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•

Listen: the hospice nurse should provide time for the patient and family to
express their wishes, concerns, and goals related to medication.

•

Develop: the hospice nurse and patient/family should develop a patientcentered plan of care that incorporates discontinuing inappropriate
medications that is aligned with the patients' goals.

In educational session four, conducted in the fourth week of September 2021, the
DNP student focused on role-playing case studies that required participants to practice
integrating the knowledge gained through sessions one through three. Each nurse roleplayed the part of the nurse and the part of the patient in a supportive environment.
Measurements
The DNP project used quantitative data collection methods: a pre-post
questionnaire, a confidence ruler, retrospective chart reviews, and a program evaluation.
The pre-post questionnaires allowed hospice nurses to evaluate their knowledge of
deprescribing principles, prescribing cascade, polypharmacy, STOPP frail criteria,
deprescribing algorithms, and the BUILD model. The prequestionnaire also included five
questions on nursing experience, academic level, and experience as a hospice nurse.
The participants' responses were rated as either correct (1 point) or incorrect (0
points). Higher points meant a more substantial knowledge base. Five of the participating
nurses tried the questionnaire to determine its clarity. All five hospice nurses completed
the questionnaire without difficulty and reported that the questionnaire was easy to
complete and understand. In the small sample test performed by five hospice nurses, the
pre-and post- questionnaire demonstrated face validity. (See Appendix F)
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The pre-and-post surveys and confidence rulers measured whether the hospice
nurses who attended the educational sessions gained expertise and confidence. The
Confidence ruler assessed the participant's confidence level of deprescribing (See
Appendix G). The tool evaluated where the learner was on the confidence scale and
identified what needed to occur to change their practice (Gold & Kokotailo, 2017).
In addition, an educational session evaluation tool was created that participants
completed after each educational session. The evaluation tool consisted of seven
questions that evaluated the content of the educational session (Appendix L). The skillbuilding case study review occurred during the last academic session. The case study was
about a 66-year-old female diagnosed with Advanced Lung Cancer admitted to hospice
services (Appendix E). Each participant was asked to assess the patient in the case study
and identify inappropriate medications using the STOPP/Frail criteria. The completion of
the skill-building case was designed to measure whether the hospice nurses demonstrated
increased knowledge about the STOPP/Frail criteria and could apply the tool in practice.
In addition, retrospective chart reviews occurred over 60 days from January
through February 2022 to identify whether conversations took place between the hospice
nurse, patients, and families about inappropriate medications that had been identified and
whether those conversations resulted in the deprescribing of medications.
Data Collection Procedures
Pre-intervention phase: The hospice nurse completed the pre-intervention survey and
confidence ruler at the beginning of the first education session in September 2021. Each
survey was coded with a number and letter to maintain anonymity. The sample size was
25 hospice nurses that the agency employed during September 2021.
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Intervention phase: During the intervention phase in September 2021, four educational
sessions were conducted. Each participant completed the education evaluation survey at
the end of each session.
Post-intervention phase: Each participant completed the post-survey and the confidence
ruler. After the educational sessions, the DNP student met individually with each hospice
nurse to review medications for deprescribing. The DNP student conducted chart reviews
during January and February 2022. The chart reviews focused on determining whether
conversations occurred between the hospice nurse, patient, and family related to
inappropriate medications that could be deprescribed and whether medications were
discontinued. Monthly medication reports confirmed that medications were discontinued
in conjunction with chart reviews. An Excel spreadsheet tracked each patient visit and the
medications that were deprescribed. Additionally, a monthly pharmacy financial report
was reviewed as well to collect information related to the fiscal impact of deprescribing.
Data Analysis
To assess the effectiveness of the intervention, descriptive and inferential
statistics were used. Each participant's responses from the pre and post questionnaire,
which focused on knowledge level, confidence level, and demographic data were
compiled in an Excel spreadsheet. Responses were then coded appropriately to input into
SPSS Version 26 for analysis and to produce frequency tables. The figures represent the
pre and post chart reviews and differences between the number of medications the patient
was on at the time of death and the fiscal impact of the intervention.
Descriptive analysis concentrated on the hospice nurses' age, nursing experience,
education level, and nursing experience as a hospice nurse. The paired T-test was used in
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inferential statistics to analyze the pre- and post-questionnaires on knowledge and
confidence level. The significance level was set at 0.05. The data on deprescribing
medications obtained from the chart reviews were coded in an Excel spreadsheet and
evaluated by the DNP student. Data was then coded appropriately to input into SPSS
Version 26 for analysis. The deprescribed medications were categorized as follows:
vitamins, aspirin, statins, diabetes, cardiac, and proton pump inhibitors. The medications
were then divided into three groups: admission, pre-intervention, and post-intervention.
The project's goals were to increase hospice nurses' knowledge of deprescribing
and increase confidence by utilizing the STOPP Frail Criteria and GPGP Algorithm
within their clinical practice. Increase the ability of hospice nurses to detect inappropriate
medications and engage in dialogues with patients and families about deprescribing using
the BUILD model.
Results
A total of 25 hospice nurses participated in the project. The participants'
demographics are presented in Table 1. The results of the demographic analysis showed
that 32 % of the hospice nurses had over 15 years’ experience as a nurse; however, 64%
of the nurses were novices with less than five years' experience within the specialty of
hospice. The participants were divided into four groups according to their level of
education, 48% of participants had a bachelor's degree, 36% had an associate degree, and
12% were LPNs. One participant (4%) had a master's degree in nursing.
Table 1
Participant Characteristics (N=25)
Demographics
Age

Category
20-30 years old
31-40 years old

N
2
5

%
8
20

23

Education

RN Experiences

Hospice RN Experiences

41-50 years old
Over 51 years old
LPN
Associates
Bachelors
Masters
0-5 years
6-10 years
11-15 years
Over 15 years
0-5 years
6-10 years
11-15 years
Over 15 years

9
9
3
9
12
1
5
6
6
8
16
6
0
3

36
36
12
36
48
4
20
24
24
32
64
24
0
12

Comparison of Pre-and post-Questionnaire
Knowledge gained about deprescribing, the STOPP Frail Criteria, and the GPGP
algorithm was measured by the post questionnaire, which results are represented in Table
2. In total, 25 hospice nurses completed the program. The overall mean score of
knowledge increased from 8.40 to 9.56 and the mean score of confidence increased from
14.28 to 23.40.
Table 2
Descriptive Statistic- Hospice Nurses' Knowledge and Confidence (N=25)

Knowledge

Confidence

Mean

N

Standard
Deviation

Standard
Error Mean

Pre-test

8.4000

25

.81650

.16330

Post-test

9.5600

25

.71181

.14326

Pre-test

14.2800

25

6.21504

1.24301

Post-test

23.4000

25

5.28362

1.05672

Table 3 presents the results of a comparison between pre and post-test knowledge.
There were significant differences in both knowledge (t=-5.642, p <.001) and confidence
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(t= 8.812, p <.001) between pre-post educational program.

Table 3
Paired T-test
95% confidence
interval of difference

N

Std.
deviation

Std.
Mean
Error

Pre-post
know.

-1.1600 25

1.02794

.20559

-1.58431

Pre-post
conf.

-9.1200 25

5.17462

1.03492

-11.2258

Mean

lower

t

df

One
sided
p

-.73569

-5.642

24

<.001

<.001

-6.48402

-8.812

24

<.001

<.001

upper

Deprescribing Medications
Table 4 displays the type of medications prescribed to the 99 patients that had
their records reviewed prior to the hospice nurses receiving the education and how many
medications they were on following the intervention. A total of 98 patients had
medications deprescribed by the hospice nurses who participated in the intervention over
a 90-day period. The most common categories of deprescribed medications included
aspirin, statins, vitamins, cardiac medications (angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, diuretics, beta-blockers, antiarrhythmics), diabetes
medications (oral medications, insulin), and proton pump inhibitors.
There were substantial variations between this project's preintervention and
postintervention phases regarding medication deprescribing. As a result of the
educational intervention, the six major medication categories that were deprescribed were
aspirin (18%), statins (14%), vitamins (26%), cardiac medications (42%), diabetes
medications (59%), and proton pump inhibitors (41%). As a result of the educational
intervention, the number of medications patients were on at the time of death had

Twosided
p
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decreased significantly (p <.0001~ <.0006).
Table 4
Number of patients on medications per drug category (N=99)
Drug Category

Admission

Aspirin
Statins
Vitamins
Cardiac
Medications
Diabetes
Medications
Proton pump
inhibitors
(PPIs)

Post
intervention
4
6
11
31

Percent
deprescribed
18%
14%
26%
42%

P value

22
43
47
73

Pre
intervention
20
39
44
73

32

32

19

59%

0.0006

34

34

14

41%

<.0001

0.0002
<.0001
<.0001
<.0001

The percentage of patients who received 0-9 medications increased to 59% postintervention. The percentage of patients who received >20 medications decreased to 0%,
as demonstrated in Figure 1 below.
Figure 1
Medications at Time of Death Pre/Post Intervention

Medications at Time of Death
70%
59%

60%
50%

39%

40%

Pre-intervention

31%
30%

Post-intervention
18%

20%
10%

3%

0.00%

0%
meds 0-9

meds 10-19

meds >20

The results showed a substantial number of deprescribed medications because of
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this educational intervention. This is clinically significant because the hospice nurses'
knowledge and confidence gained from these educational sessions were utilized in
clinical practice to reduce the polypharmacy and adverse effects of medications during
the end of life.
Fiscal Impact of Deprescribing
As a result of deprescribing, the agency saw a reduction in medication
costs over the 90 days after the educational intervention, as illustrated in Figure 2. Before
the intervention, the cost of medications over three months was $72,767.30. During the
three months, October 2021 through December 2021, post-intervention, the total cost of
medications was $54,250.00. Post-intervention the costs of the medications were reduced
by $18,517.30. Additionally, the cost of medications per patient per day also decreased
from $7.80 to $6.10.
Figure 2
Medication costs pre/post intervention

Cost of Medications
35,000.00

32,639.66

30,000.00

25,000.00
21,174.99

21,952.70

20,000.00
15,678.99
15,000.00
10,000.00
5,000.00
0.00

18,201.94
16,396.03

Pre intervention
Post intervention
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Achievement of Outcomes (Appendix M)
Goals 1. The outcome was to have 100% of participating hospice nurses self-assess their
current knowledge of deprescribing principles, prescribing cascade, polypharmacy,
STOPP frail criteria, deprescribing algorithms, and the BUILD model prior to and
following educational sessions. This goal was met since 100% of hospice nurses
completed self-assessments prior to and after the educational intervention.
Goal 2. The outcome was to have 100% of participating hospice nurses self-assess their
confidence with deprescribing. This goal was met since 100% of hospice nurses
completed their confidence with deprescribing before and after the intervention.
Goals 3. The outcome was to have at least 80% of hospice nurses participate in
comprehensive education, including four 60-minute sessions. This goal was met since
89% of hospice nurses participated in all four educational sessions.
Goal 4. This outcome was to have at least 80% of hospice nurses demonstrate increased
knowledge, confidence with deprescribing and the use of deprescribing tools as measured
by their self-assessments. This goal was met since 88% of hospice nurses showed
increased knowledge and confidence with deprescribing and utilizing screening tools in
their clinical practice.
Goal 5. The outcome was to have at least 80% of patients under the care of participating
hospice nurses had 1-2 futile medications deprescribed within 90 days of the educational
sessions based on retrospective chart reviews. This goal was met since 99% of patients
had at least one medication identified as inappropriate and then deprescribed.
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Discussion
Hospice nurses improved their knowledge and confidence in clinical practice by
attending these educational sessions on deprescribing, polypharmacy, and evidence based
deprescribing screening tools. However, it is more than just the knowledge of and the
utilization of screening tools. Deprescribing involves a higher-level skill set which
includes critical thinking, strong clinical assessment skills, medication reconciliation, and
a trusting relationship with patients and families. To develop clinical proficiency,
participants needed to apply the skills gained in each of the four educational sessions.
The results demonstrate that the educational sessions increased the hospice nurse's
knowledge and confidence level with deprescribing. As a result of the improved
knowledge, hospice nurses expanded the number of conversations they had with patients
and families. Hospice nurses developed greater confidence from the use of their tool kits
and the increased understanding enabled them to undertake these conversations earlier in
the patient treatment and earlier in the disease trajectory.
The educational session focused on the BUILD model shifted the participants'
dialogues with patients and families by emphasizing a collaborative communication
process between the hospice nurse, patient, family, and physician. The collaborative
nature of these conversations encouraged patient-centered treatment decisions that were
aligned with the patients' goals. As mentioned previously, the strengthening of
relationships enabled hospice nurses to take the lead in initiating these difficult
conversations. This project supported the theme identified in the Burgle et al. (2020)
study, which states that deprescribing medications involves the whole team of
practitioners, patients, and families.

29

The team-based approach during the educational sessions integrated the use of
case studies to require participants to combine both theory and reality. Participants had to
comprehend and apply the concepts and theories they learned to practical situations.
Participants were to practice in a secure and supportive environment since the case
studies were conducted in this way.
The hospice nurses participated indirect use of the GPGP algorithm and STOPP
criteria in their individual meetings, which assisted them in identifying medications that
were no longer appropriate for the patient. As a result, 99% of patients had 1-2
inappropriate medications deprescribed. The most significant impact of medication
deprescribing occurred within three medication categories: diabetes medications (59% of
patients), cardiac medications (42% of patients), and proton pump inhibitors (41% of
patients). The results of this project support the notion that providing education to
hospice nurses on deprescribing and the use of deprescribing tools and conversational
frameworks strengthen their confidence level and expertise, allowing them to discuss the
discontinuation of medications with patients and families. This pattern of results is
consistent with the previous literature by Curtin et al. (2017), who conducted a clinical
trial in Ireland which utilized the STOPP criteria intervention for 51 participants within a
sample size of 130. As a result of the intervention of the STOPP criteria, 91% of the
participants received recommendations to stop at least one inappropriate medication.
Strengths
The nurses expressed interest in learning about deprescribing medications near the
end of life, which helped this project be successful. This passion created a path for
practice transformation that improved patient outcomes. Additionally, the two
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standardized screening tools, the STOPP Frail Criteria and the GPGP algorithm, assisted
the hospice nurses in identifying inappropriate medications at the end of life and, when
applied allowed them to provide standardized deprescribing practice. The findings of the
pre- and post-questionnaires show a strong correlation between enhanced knowledge and
confidence with deprescribing and integration in clinical practice and a reduction in
polypharmacy.
Hospice nurses played a vital role in educating the patient and families about the
benefits of deprescribing and how it could enhance the quality of life. As seen in previous
literature, there was a correlation between the intricacy of the medication regimen and the
patients and family's sense of pill burden. The opportunity to deprescribe became
apparent when the patients and families became aware of polypharmacy's burden.
Another strength of this project was the collaboration among the interdisciplinary
team members, including hospice nurses, physicians, pharmacists, patients, and families
to develop patient-centered plans of care that aligned with the patients' goals. The
inclusion of a pharmacist and one-to-one meetings with the hospice nurses allowed the
discovery of duplicative therapy, drug-to-drug interactions, inappropriate medications,
and the efficacy of the patient's medication regimen. In addition, the hospice nurses felt
empowered to initiate these conversations earlier along the disease trajectory.
Inappropriate medications were deprescribed because of this strategy and patients'
outcomes were improved.
Limitations
Although the present results clearly support that there is a correlation between
increased practitioner knowledge, confidence, and strong patient/family relationships and
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the deprescription of medication, it is appropriate to recognize potential limitations. One
of the limitations of this project was the small sample size (n=25) of hospice nurses who
could participate in all four educational sessions. The potential of unforeseen clinical
emergencies that can occur at end of life prevented all hospice nurses from participating
in the educational sessions. Furthermore, this agency's geographic region prevented
participants from returning to the office to participate in the educational sessions. The
COVID-19 pandemic caused significant staffing shortages which reduced the amount of
time that hospice nurses were able to dedicate to the educational sessions due to each
hospice nurses' higher patient census.
Another project drawback is that the pre-intervention patient group and the postintervention patient group could not be compared due to the short length of stay of the
pre-intervention group prior to death. The data on medicine deprescribing comes only
from the post-intervention sample. The data compares the medications prescribed to each
patient on admission to the medications that were deprescribed prior to the first
educational session and medications that were deprescribed after all four educational
sessions. Even though the project's data is only from the post-intervention patient
population, it still demonstrated clinical significance. Despite these limitations, these
results suggest theoretical and practical implications.
Clinical Implications
With enhanced understanding and confidence regarding deprescribing, hospice
nurses are now more equipped to have these discussions with patients when their
conditions change. Examples of the changes in condition that were seen by the hospice
nurses included admission to hospice, dysphagia, change in cognitive status or
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consciousness, increase in falls, increase in pain, and when the patient can no longer take
in oral intake. Within the clinical practice of hospice nurses, the concepts of
deprescribing and medication reconciliation became a standardized process. The hospice
nurses were able to effectively address duplicative therapy, drug-to-drug interactions, and
inappropriate medications after implementing the knowledge and confidence they
acquired from this educational intervention. This improved patient outcomes and
symptom management through the end of life. The clinical implication of this project was
that medication safety in a hospice patient's paramount.
Conclusion
This project's results contribute to a growing body of evidence suggesting that the
training contained in the educational program increased the hospice nurses' confidence
and understanding about deprescribing. The training also enabled the hospice nurses to
incorporate the knowledge gained into their clinical practice. The application resulted in
behavioral shifts among the hospice nurses that significantly impacted hospice patients'
quality of life and symptom management. Deprescribing medications for hospice patients
is a complicated and pivotal process that requires a systematic approach. The educational
intervention provided participants with the tools necessary to develop a tool kit. These
tools included two evidence-based screening tools (i.e., STOPP Frail Criteria and GPGP
algorithm) and a standardized framework (i.e., BUILD model). Furthermore, the project
improved participants' clinical confidence and experience, allowing them to grow into
seasoned hospice nurses. Patient safety necessitates the deprescribing of drugs at the end
of life.
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Future Recommendations
All nurses in any clinical practice can benefit from the educational intervention
used in this project. The educational sessions could be used as part of a training program
or continuing education. In terms of future research would be useful to extend the current
findings by examining the impact of these interventions on varied patient populations
across the healthcare industry. The educational program will be implemented at the
organization's sister hospice agency. If, as the present study suggests, there is a
correlation between the interventions utilized and deprescribing medications, more
research into the influence of deprescribing on patient outcomes should be considered.
Studies could focus on reducing adverse effects of polypharmacy at end of life, the
potential for improved quality of life, and the impact across socioeconomic and ethnic
subgroups.
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Appendix D Education Design Outline
Objectives
Learner objectives

Preintervention

Pre-intervention
questionnaire

Session One

•
•
•
•

Session
Two

•
•
•

Session
Three

•
•
•

Session
Four

•
•
•

•

Content

Methodology

Time

Evaluation

Outline of the
content/topic to be
presented and indicate
which objective(s) the
content/topic is related.

Teaching strategies
(audio/visual/discussio
n) used for each
topic/content area.

Period for the
content/topic
area.

Activities/approaches to
determine knowledge
gain of participants

Individual
questionnaire

15 min.

Assess knowledge of
deprescribing before
educational sessions
Assess the level of
confidence and comfort
with deprescribing

Define
Deprescribing and
Polypharmacy
Define Prescribing
Cascade
Identify indications
for Deprescribing.
Identify adverse
effects of
polypharmacy.
Identify
Deprescribing
Screening Tools
Review how to
utilize tools in
clinical practice.
Identify standard
medication classes
to target for
deprescribing.

•

Review and
Define concepts of
Deprescribing and
Prescribing
Cascade

•

Lecture (PP)

Total 60 min
(45 min. and
15 min. for
questions)

•

•

Lecture Format
(PP)
Each participant
will receive
laminated copies
of the Garfinkel
algorithm and
STOPP Frail
Criteria

Total 60 min
(45 min. and
15 min. for
questions)

80% of participants will
be demonstrate using the
tools for deprescribing.
They will identify one
inappropriate medication
using deprescribing tools

Review BUILD
Model
Identify five
components of the
BUILD Model.
Define strategies on
how the BUILD
model is useful
when deprescribing.

•

Review
Deprescribing
Tools:
STOPP/Frail
Criteria
Garfinkel
Deprescribing
Algorithm
NHPCO
Deprescribing
Tool kit
Theoretical
Framework:
BUILD MODEL –
formalized process
to assist hospice
nurses with
deprescribing
conversations.

•
•

Lecture (PP)
Each participant
will receive a
laminated copy
of the BUILD
Model

Total 60 min
(45 min. and
15 min. for
questions)

80% of participants will
demonstrate how to use
the BUILD model
during conversations
with patients.

Reviewing
components for
deprescribing
Gain confidence
with deprescribing
tools
Perform
deprescribing
techniques through
role-playing.
Assess personal
knowledge,
confidence after
implementation of
deprescribing.

•

Review Case
studies and roleplaying scenarios

•
•
•

Lecture (PP)
Case studies
Role-Playing
using tools

Total 60 min
(45 min. and
15 min. for
questions)

80% of participants will
implement deprescribing
tools through roleplaying a case study.

•
•
•

•

•

Posttest to be completed
to reassess comfort and
confidence of
deprescribing

45

Postintervention

Post-intervention
questionnaire

Individual
questionnaire

15 min.

Assess knowledge of
deprescribing before
educational sessions
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Appendix: E Case Scenario for Role Play
SA is a 66-year-old female referred to a hospice following three hospitalizations in the
last three months. She has a diagnosis of advanced Lung Cancer. She has metastasis to
the liver, bone, and lymph nodes. She is short of breath with minimal exertion and
experiencing significant pain. She has bilateral lower extremity edema 2+. She has
decided that she does not want to return to the hospital. She is having difficulty with
ambulation with a history of falls. Her appetite is decreasing. She has no caregiver in the
home.
Current medications include:
Simvastatin for Hyperlipidemia
Alendronate for Osteoporosis
Levothyroxine for Hypothyroidism
Lasix for edema
Trazadone for sleep
Multi-vitamin
MS Contin long-acting pain medication
Morphine sulfate for pain and shortness of breath
Docusate for constipation
Ativan for anxiety

1. Would it be appropriate to discontinue any of these medications?
2. Utilizing the STOPP/Frail Criteria which medication(s) were identified that are no
longer indicated or inappropriate for this patient?

47

Appendix F Deprescribing Knowledge
1. Polypharmacy and inappropriate medications may cause adverse effects for
patients nearing end of life.
True
False
2. Polypharmacy is defined as using multiple medications typically five or more,
whose harms outweigh the benefits.
True
False
3. In the deprescribing process, medication reconciliation is not required.
True
False
4. Hospice nurses have no role in identifying potentially inappropriate medications.
True
False
5. The STOPP/Frail Criteria tool is used to guide hospice nurses in the identification
of inappropriate medications.
True
False
6. Deprescribing algorithms are only used by providers.
True
False
7. Prescribing cascade is a misinterpretation of an adverse drug reaction as a
symptom of
another condition.
True
False
8. Deprescribing medications is a systematic process of reducing or discontinuing
inappropriate medications.
True
False
9. The BUILD Model is used to conduct research on medications.
True
False
10. Medications that are frequently inappropriate at end of life are statins,
anticoagulants, bisphosphonates, and proton pump inhibitors.
True
False

Demographic Questions
1. How long have you been a nurse?
___ (0-5 yrs.) ____ (6-10 yrs.) ___ (11-15 yrs.) ___ (over 15 yrs.)
2. How long have you working as a hospice nurse?
___ (0-5 yrs.) ____ (6-10 yrs.) ___ (11-15 yrs.) ___ (over 15 yrs.)
3. How old are you?
___ (20-30) ___ (31-40) ___ (41-50) ____ (over 50)
4. What is your highest degree in nursing?
____ Associates ____ Bachelors ____ Masters _____ LPN
Appendix G
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Appendix G My Confidence Ruler
Name (ID Code) ___________

Date_____________

Using the scale below, rate how confident you are with deprescribing, zero describing not
confident, and ten being extremely confident.
1. How confident are you today identifying inappropriate medications for patients at the
end of life using the Garfinkel algorithm and STOPP/Frail criteria?
______________________________________________________________
0

1

2

3

4

5

6

7

8

9

Not at all
Confident

10
Extremely
Confident

2. How confident are you today in recommending deprescribing of preventative
medicines for hospice patients when life expectancy no longer justifies potential
benefits?
____________________________________________________________
0

1

2

3

4

5

6

7

8

9

Not at all
Confident

10
Extremely
Confident

3. How confident are you today in your ability to recommend appropriate deprescribing
strategies for potentially inappropriate medications in clinical practice?
______________________________________________________________
0

1

2

3

4

5

6

7

8

Not at all
Confident
Why are you at _____ and not zero?
What would it take to go from ____ to _____ (highest number)?

(Gold & Kokotailo, 2017)

9

10
Extremely
Confident
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Appendix H UMASS IRB Letter
Mass Venture Center
100 Venture Way, Suite 116
Hadley, MA 01035
Telephone: 413-545-34

Memorandum – Not Human Subjects Research Determination

I.

Date: July 2, 2021
To: Shannon Dickson, Nursing
Project Title: Deprescribing medications at end of life at a Community Hospice Agency
HRPO Determination Number: 21-125
The Human Research Protection Office (HRPO) has evaluated the above-named project and has made the following determination
based on the information provided to our office:
☐ The proposed project does not involve research that obtains information about living individuals
[45 CFR 46.102(f)].
☐ The proposed project does not involve intervention or interaction with individuals OR does not use identifiable private
information [45 CFR 46.102(f)(1), (2)].
☒ The proposed project does not meet the definition of human subject research under federal regulations [45 CFR 46.102(d)].
Submission of an Application to UMass Amherst IRB is not required.
Note: This determination applies only to the activities described in the submission. If there are changes to the activities described in
this submission, please submit a new determination form to the HRPO prior to initiating any changes. Researchers should NOT
include contact information for the UMass Amherst IRB on any project materials.
A project determined as "Not Human Subjects Research," must still be conducted ethically. The UMass Amherst HRPO strongly
expects project personnel to:

-

treat participants with respect at all times
ensure project participation is voluntary and confidentiality is maintained (when applicable)
minimize any risks associated with participation in the project
conduct the project in compliance with all applicable federal, state, and local regulations as well as UMass Amherst
Policies and procedures which may include obtaining approval of your activities from other institutions or entities.

Please do not hesitate to call us at 413-545-3428 or email humansubjects@ora.umass.edu if you have any questions.

Iris L. Jenkins, Assistant Director
Human Research Protection Office
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Appendix I HCIB IRB Letter
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Appendix J Cost Benefit Analysis

Description

Cost

Quality Printing GPGP and

$50.00

STOPP Frail Screening tools

Lamination and key rings

$10.00

Clinical Staff cost in education ($35x 20)

$700.00.

Programs
Total

$760.
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Appendix K Timeframe

July

Sept.

Oct-

March
Task

2021

2021

Jan-Feb

April

2022

2022

Dec.

2021
2021
Meet with key stakeholders,
Executive Director, and
Management team.
Proposal Approved by DNP
Committee
Obtain IRB approval

XX
XX

XX

Pre-intervention questionnaire to
all hospice nurses on
deprescribing

XX

Educational sessions for hospice
nurses on Build Model, STOPP
Criteria, Role-playing,
algorithms will commence.

XX

Implementation of data
collection on deprescribing
Post-intervention questionnaire
to hospice nurses
Data analysis and evaluation of
outcomes
Review outcomes with ED and
Senior Management of Agency.
Consider practice change.

XX
XX

XX

XX
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Appendix L Educational Program Evaluation

Date __________

Name ______________________

1. Was the program presented at a convenient time? Yes____ No ____
2. Was the program conducted at a convenient location? Yes _____ No____
3. Was the room conducive to learning? Yes _____ No ______
4. What did you learn from this educational presentation?

5. What recommendations do you have for improvement?

6. What recommendations do you have for facilitator or participant engagement?

7. What other learning opportunities would you like related to this topic?
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Appendix M Goals and Outcomes
Goal
The DNP student
assessed hospice
nurses' current
knowledge of
deprescribing
principles, the
definition of
prescribing cascade,
and current
confidence in
deprescribing.
The DNP student
provided
comprehensive
education, including
a portable toolkit
that focuses on
deprescribing to
hospice nurses.
The DNP student
measured knowledge
and confidence with
deprescribing of
hospice nurses after
the educational
sessions.

The DNP student
monitored the
hospice nurse's
implementation of
screening tools to
identify
inappropriate
medications while
performing
medication
reconciliation with
patients

Objective(s)
The DNP student
conducted a prequestionnaire
knowledge and
confidence rating
screen of hospice
nurses' before
providing the
educational
workshops in
September 2021.
The DNP student
provided four (4)
sixty-minute
educational
workshops during
September 2021.
The DNP student
conducted a postknowledge
questionnaire and
confidence rating
screen of hospice
nurses after the
education sessions at
the end of September
2021.
The DNP student
conducted chart
reviews, joint visits
and had a 1 to 1
meeting with hospice
nurses to review the
medication identified
for deprescribing by
December 2021.
The DNP student
conducted chart

Projected
Outcome(s)
100% of hospice
nurses completed
the prequestionnaire.

Outcome
Met: 100% of
hospice nurses
completed the
prequestionnaire

80% of hospice
nurses attended all
four of the sixtyminute educational
presentations
measured through
attendance sheets.

Met: 89% of
hospice nurses
attended all
educational
sessions. (N25)

80% of hospice
nurses increased
their knowledge and
confidence about
deprescribing and
screening tools, as
evidenced through
their postquestionnaire.

Met: 88%
demonstrated
increased
knowledge and
confidence on
the postquestionnaire.

80% of hospice
nurses recorded the
medication(s)
identified as
inappropriate for
their patients and
documented their
conversations with
patients in their
chart.

Met: 100% of
nurses
documented
medications
within the EMR
that were
identified for
deprescribing.
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reviews to monitor
documentation for
conversations with
patients/families
about deprescribing
inappropriate
medications by
December 2021.
The DNP student
The DNP student
evaluated hospice
performed chart
nurses'
reviews to gather
implementation of
data on medications
deprescribing
that have been
utilizing screening
deprescribed by
tools and algorithms. December 2021.

80% of patients
under the care of
participating
hospice nurses had
1-2 futile
medications
deprescribed within
60 days of the
educational
sessions.

Met: 99% of
patients had 1-2
futile
medications
deprescribed.

